Prof. Hao Shen is the president of Biosyngen Pte Ltd, a Singapore based biotech focusing on developing cutting edge immune cell therapies for cancer patients. Before joining Biosyngen, Professor Shen was the chief scientific officer of Fosun Kite and the director of the Shanghai Institute of Immunology. As a tenured professor at the University of Pennsylvania, Professor Shen has received multiple accolades. With over 120 published papers, his research focuses on T cell immunology and has led to significant advancements in cancer therapeutic vaccines.